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by the price reduction (“targeted”) or not (“non-targeted”). We used an interrupted
time series design and segmented regression models to estimate changes in
monthly per capita volume (DDD) and expenditures following the policy. RESULTS:
A total of 72.6% (130/179) of products were targeted by the policy. Biguanides,
sulfonylureas, alpha-glucosidase inhibitors, and thiazolidinediones accounted for
96.8% of oral antidiabetic volume and 93.3% of expenditures. After the policy, there
were reductions in the volume trend (-3.04 DDD/patient/month; 95%CI, [-4.98,
-1.10]) and expenditure trend (-61.76 NT$/patient/month; [-75.00, -48.51]) of tar-
geted medications. Growths in the market volume and expenditures for non-tar-
geted products were stable with no notable changes following the policy. Effects
differed by drug group: use of targeted biguanides remained stable, but expendi-
tures fell by 167 NT$/patient immediately after the policy; use of targeted sulfonyl-
ureas and expenditures also reduced (-2.39 DDD/patient/month [-3.00, -1.78]; 204
NT$/patient immediately after the policy); and use of targeted thiazolidinediones
decreased (-0.58 DDD/patient/month [-0.81, -0.35]). In contrast, use and expendi-
tures for non-targeted biguanides and alpha-glucosidase inhibitors increased,
while non-targeted sulfonylureas remained stable. CONCLUSIONS: Overall, the
price reduction policy resulted in lower use and expenditures for targeted oral
antidiabetics medications, but reductions in market growth for several classes of
targeted products and increases in use of non-targeted products. Our results sug-
gest that the price reduction impacts may differ among specific anti-diabetic drug
groups.
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OBJECTIVES: Individuals with diabetes are particularly susceptible to influenza
and pneumonia infection. They are recommended to receive annual influenza
vaccination during flu season and at least one pneumonia shot during lifetime. The
Healthy People 2010 Initiative set a goal of vaccinating 90% of those diabetic adults
over 65 years old and 60% among diabetic patients less than 65 years of age. Vac-
cination coverage among diabetic adults in the United States, however, is
understudied. METHODS: We analyzed the 2006-2010 National Health Interview
Survey (NHIS) data to 1) estimate the influenza and pneumococcal vaccine cover-
age rates among adults with diabetes over the 5-year study period adjusting for
weights, and 2) identify factors that are potentially associated with both vaccina-
tions among this population using multiple logistic regression. RESULTS: Among
diabetic adults aged 18 to 64 years old, both influenza and pneumonia vaccination
coverage decreased in 2007 and increased steadily from 2008 (weighted estimates:
47.5% for influenza and 32.2% for pneumonia) to 2010 (weighted estimates: 53.4%
for influenza and 38.2% for pneumonia). For those aged 65 years or older, influenza
vaccination coverage was relatively stable from 2006 to 2009 but reduced in 2010.
Pneumonia vaccination rates did not vary much from 2006 to 2010. Overall, both
coverage levels were substantially higher among the aged group. Factors that pos-
itively associated with vaccinationwere 65 years or older, high school education or
above, being married, having a health insurance, formal smoking, longer duration
of being diabetic, having at least one comorbid chronic condition, having more
than 2 physician encounters in last 12 months. CONCLUSIONS: The influenza and
pneumonia vaccination coverage increased marginally among adults with diabe-
tes from 2006 to 2010 but the objective of Health People 2010 had not achieved yet.
Special efforts could be implemented to enhance both vaccine coverage among
diabetic adults.
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OBJECTIVES: Opioid use has grown over the last decade and neuropathy and dia-
betic peripheral neuropathy (DPN) guidelines do not recommend opioids as first
line treatment. This study sought to examine the proportion of DPN patients who
are prescribed opioids and to determine the proportion of DPN patients who are
prescribed opioids as first line treatment.METHODS:A 10% sample of IMS-LifeLink
claims data from 1998 through 2008 were used. The study population consisted of
patients with 1 diagnosis for diabetes and/or 1 claim for an antidiabetic pre-
scription. DPN patients were identified with a validated DPN identification algo-
rithm; and the first date of a DPN diagnosis served as the index date. All patients
were required to have continuous 12 month pre- and post index date plan enroll-
ment and be 17 years of age. Patients with cancer, non-cancer pain conditions,
surgery in the pre- and post- 12 month index period, and with opioid use in the
pre-index period were excluded. Descriptive statistics including demographic
Charlson-comorbidities, with first line use of DPN related medications were
calculated. RESULTS: A total of 984 DPN patients met inclusion exclusion criteria
with a mean age of 60.08 years. 37.40% were female and 29.88% used insulin. 428
DPN patients (43.49%) received DPN pharmacologic treatment. Of those with DPN
pharmacologic treatments, 91 (21.26%) received opioid as first line treatment. An-
tidepressants, anticonvulsants and NSAIDs were initially used by 28.97%, 23.60%,
and 21.96% respectively. The most commonly used opioids were hydrocodone
combinations (8.03%), followed by codeine combinations (2.64%) and oxycodoneCR
(2.44%). Factors associated with opioid use will be reported. CONCLUSIONS: Over
50% of DPN patients remained untreated with pharmacologic therapy after a DPN
diagnosis, which may reflect under-treatment. Despite DPN treatment guidelines
that do not recommend opioids as first line treatment, opioids were among the
most common first line agents used.
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OBJECTIVES: To explore the association between race and the use of Thiazolidin-
ediones (TZDs) and metformin among patients with Type II diabetes in the Mary-
land Medicaid population. METHODS: Medical/prescription/enrollment records
from the Maryland State Medicaid Managed Care Organization/Fee-for-service,
ages 18 or older, initiating use of either metformin or TZDs between 7-1-05 and
12-31-09, followed for 6months. Variations in race over TZDs andmetformin use
are described. Logistic regressions assess the likelihood of 1) starting on TZDs over
metformin, and 2) switching to a TZD given initial use ofmetformin. Models adjust
for other anti-diabetic agents, demographics, and comorbidities: hyptertension
(HTN), hyperlipidemia (HLD), liver disease (LD), renal dysfunction (RD). RESULTS:A
total of 25,758 started on metformin (N19910) or TZDs (N5848). 20% of patients
started on metformin used TZDs later, and 47% of patients started on TZDs used
metformin later. 24% of Caucasians (N8570), 21.5% of African-Americans
(N14094), 22% of Hispanics (N987), and 28.6% of other races (N1,201) were
started on TZDs. 20% of Caucasians started onmetformin switched to TZDs; as did
18% of African-Americans, 22% of Hispanics, and 24% of other races. Logistic re-
gression shows that African-Americans (OR0.88, 95%CI: 0.82-0.95) and Hispanics
(OR0.80, CI: 0.68-0.95) were less likely than Caucasians to be started on TZDs.
Males (OR0.92, CI: 0.86-0.98) were less likely than women, likelihood of initiation
on TZD increases with age or RD (OR1.91, CI: 1.62-2.25), and decreases if HTN
(OR0.64, CI: 0.59-0.69), HLD (OR0.68, CI: 0.62-0.74), or LD (OR0.48, CI: 0.37-0.63)
are present. Therewas no association between race and the likelihood of switching
to TZD once started onmetformin. There was no evidence of sample selection bias
in the lattermodel. CONCLUSIONS:Minority diabetic patients were less likely than
Caucasians to be started on TZDs rather than metformin.
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OBJECTIVES: Compare patient characteristics, medication use, diabetes-related
charges, and resource utilization between patients with Type 2 diabetes (T2DM)
who initiated therapy with an oral fixed combination (OFC) therapy and those
treated with two medications which are available in OFC formulation (dual).
METHODS:Data for this studywere obtained from the i3 inVision™databases over
the time period from January 1, 2006 through June 30, 2010. The analyses compares
patients who initiated therapy on an OFC (N4271) to those who initiated on two
classes of oral medications which are available in an OFC combination (N1780).
Patients were followed for 2 years post initiation and all analyses are descriptive in
nature.RESULTS: Patientswho initiated on anOFC, compared to those treatedwith
dual oral medications, were less likely to be diagnosed with a microvascular
(14.17% vs. 17.02%: p0.0046) or macrovascular (10.68% vs. 14.21%; P0.0001) com-
plication in the pre-period, although they weremore likely to be prescribed an ACE
(11.59 vs. 7.64%; P0.0001), ARB (9.58% vs. 4,44%; P0.0001), or statin (13.28% vs.
10.67%; P0.0001) in the pre-period. Use of OFC, compared to use of dual therapies,
was associated with a significant reduction in post-period hospitalization rates
(15.83% vs. 21.80%; P0.0001) as well as a lower likelihood of an ER visit (2.39% vs.
3.48%; P0.0168) and lower diabetes-related inpatient ($2174 v $3034; P0.0020),
outpatient ($2490 vs. $2,870; P0.0042), drug ($1576 vs. $2084; P0.0001) and total
charges ($6,250 v $8,019; P0.0001). Use of an OFC was associated with a signifi-
cantly higher medication possession ratio (0.58 vs. 0.51; P0.0001) and such pa-
tients were less likely to have a gap in the medication therapy of 60 days or more
(32.76% vs. 37.81%; P0.0002). CONCLUSIONS: The use of an OFC was associated
with improved patient adherence and lower diabetes-related charges compared
the dual cohort.
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OBJECTIVES: To investigate insulin injection treatment patterns and treatment
restrictions, in particular nurse administered insulin injections, on Type 2Diabetes
(T2D) patients receiving care from home healthcare agencies (HHAs), skilled nurs-
ing facilities (SNFs), and veterans affairs (VA) facilities in the United States.
METHODS: Medical directors and other knowledgeable clinical personnel from 67
HHAs, 60 SNFs, and 49 VA facilities completed online surveys in December 2008 to
January 2009 and in December 2010 to January 2011. The VA surveys covered three
VA settings: medical/surgical inpatient (VA-MS), mental health/substance abuse
inpatient (VA-MH/SA), and adult day rehabilitation (VA-ADR). RESULTS:Amajority
(67%) of HHA respondents reported that patients received one injection per day,
while two injections per daywas themost commonly reported number among SNF
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